These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36737768)

  • 1. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
    Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
    World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
    J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and without immunotherapy: a retrospective cohort study.
    Liu L; Liu Y; Xu L; Ding Y; Han J; Wang Q; Chen X; Almhanna K; Han C; Wang L
    J Thorac Dis; 2024 Jun; 16(6):3909-3922. PubMed ID: 38983179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
    Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Xu J; Cai Y; Hong Z; Duan H; Ke S
    Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of Short-term Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy and Surgery Alone for Locally Advanced Resectable 
Non-small Cell Lung Cancer].
    Li H; Liu Q; Li B; Chen Y; Lin J; Meng Y; Feng H; Zheng Z; Hui Y
    Zhongguo Fei Ai Za Zhi; 2024 Jun; 27(6):421-430. PubMed ID: 39026493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells.
    He Y; Yang D; Lin X; Zhang J; Cheng R; Cao L; Yang L; Zhang M; Shi X; Jin X; Sun H; Sun H; Zang J; Li Y; Ma J; Nie H
    Front Immunol; 2024; 15():1412693. PubMed ID: 39076970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study.
    Fei K; Guo G; Wang J; Wang Z; Wang Y; Hao X; Zhong J; Guo Q; Guo W; Su W; Zan L; Xu J; Tan F; Zhuang X; Duan J
    Front Oncol; 2023; 13():1145303. PubMed ID: 37064108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis.
    Wang M; Dong W; Liu A; Lai T; Zhang B; Sun Q
    Transl Cancer Res; 2024 Jun; 13(6):2735-2750. PubMed ID: 38988921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis.
    Zhao J; Hao S; Li Y; Liu X; Liu Z; Zheng C; Han D
    Immunotargets Ther; 2023; 12():113-133. PubMed ID: 38026088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
    Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
    J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
    Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
    Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.